Toremifene (Fareston)

Subscribe to Selected New Research on Toremifene

292 relevant articles (42 outcomes, 80 trials/studies) found for this Drug

Description: A first generation selective estrogen receptor modulator (SERM). Like TAMOXIFEN, it is an estrogen agonist for bone tissue and cholesterol metabolism but is antagonistic on mammary and uterine tissue.

Also Known As:

Fareston; FC-1157a; Toremifene Citrate; Toremifene Citrate (1:1); Toremifene, (E)-Isomer; Citrate, Toremifene; FC 1157a; FC1157a; Ethanamine, 2-(4-(4-chloro-1,2-diphenyl-1-butenyl)phenoxy)-N,N-dimethyl-, (Z)-

Relationship Network

Drug Context: Research Results

Organic Chemicals: 40

Hydrocarbons: 382

Cyclic Hydrocarbons: 2

Aromatic Hydrocarbons: 115

Benzene Derivatives: 9

Benzylidene Compounds

Stilbenes: 39

Tamoxifen: 7587

Toremifene: 292

alpha-sulfoxytoremifene

Experts

1.	Holli, K: 4 articles (10/2003 - 10/2000)
2.	Marinucci, Lorella: 3 articles (09/2008 - 04/2002)
3.	Balducci, Chiara: 3 articles (09/2008 - 04/2002)
4.	Lilli, Cinzia: 3 articles (09/2008 - 04/2002)
5.	Locci, Paola: 3 articles (09/2008 - 04/2002)
6.	Steiner, Mitchell S: 3 articles (04/2008 - 03/2002)
7.	Smith, Matthew R: 3 articles (04/2008 - 01/2002)
8.	Ellmén, J: 3 articles (11/2003 - 01/2000)
9.	Stabellini, Giordano: 2 articles (09/2008 - 03/2005)
10.	Sieber, Paul: 2 articles (04/2008 - 09/2006)

Related Diseases

1.	Breast Neoplasms (Breast Cancer) 08/01/1990 - "The efficacy of high dose toremifene (240 mg daily) in postmenopausal women with advanced breast cancer is investigated in this ongoing study" 04/01/1998 - "CONCLUSIONS: Based on these results, we consider the addition of high-dose toremifene to the CAF therapy to be useful in the treatment of advanced and recurrent breast cancer." 05/01/1997 - "Toremifene, in doses up to 240 mg/d, is an effective, safe treatment for postmenopausal women with ER-positive/unknown advanced breast cancer." 05/01/1997 - "These trials demonstrated that 60 mg/d of toremifene is safe and effective in the treatment of advanced breast cancer in postmenopausal women" 01/01/2000 - "CONCLUSIONS: Toremifene doses of 40 and 60 mg daily were effective and safe treatments of breast cancer in postmenopausal women, and no differences in their biochemical or clinical effects were seen" Get all the results and reference details, order at left...
2.	Neoplasms (Cancer) 03/01/1998 - "Studies appeared to indicate minimal efficacy of high toremifene doses in women with ER-negative tumors, but the number of patients studied was small" 08/01/1990 - "Toremifene (200 micrograms/day) was effective in preventing the development of 7,12-dimethylbenzanthracene-induced rat mammary tumors when given po from day 28 after carcinogen administration" 02/01/1998 - "The purpose of the present study was to evaluate the tissue distribution of toremifene (TOR) in baboons following intra-tissue injections and to examine the effectiveness of intratumoral TOR therapy of baboons with various spontaneous neoplasms" 11/01/1991 - "Phase I study of toremifene in patients with advanced cancer." 08/01/1990 - "Clinical trials with toremifene should employ an indefinite treatment strategy to control tumor recurrence in adjuvant studies." Get all the results and reference details, order at left...
3.	Prostatic Neoplasms (Prostate Cancer) 09/01/2006 - "CONCLUSIONS: Toremifene decreased the incidence of prostate cancer by 1 year and had a tolerability profile comparable to that of placebo in a high risk population." 04/10/2008 - "PATIENTS AND METHODS: In an ongoing, multicenter, double-blind, placebo-controlled phase III fracture-prevention study, 1,389 men receiving ADT for prostate cancer were randomly assigned to receive toremifene (80 mg/d) or placebo" 04/10/2008 - "Toremifene improves lipid profiles in men receiving androgen-deprivation therapy for prostate cancer: interim analysis of a multicenter phase III study." 01/01/2008 - "MATERIALS AND METHODS: In an ongoing, multicenter, phase 3 fracture prevention study 1,392 men 50 years or older with prostate cancer receiving androgen deprivation therapy were randomized to 80 mg toremifene per day or placebo" 01/01/2008 - "Toremifene increases bone mineral density in men receiving androgen deprivation therapy for prostate cancer: interim analysis of a multicenter phase 3 clinical study." Get all the results and reference details, order at left...
4.	Aggressive Fibromatosis (Desmoid) 09/01/2008 - "The reduction in receptor number only in desmoid cells suggests that toremifene may reduce TGFbeta1's affinity for its receptors" 09/01/2008 - "Toremifene reduced TGFbeta1 receptors only in desmoid fibroblasts, with no effect on the changes in type I, II, and III receptors" 11/01/2001 - "Synthesis and secretion of transforming growth factor-beta1 by human desmoid fibroblast cell line and its modulation by toremifene." 10/01/1999 - "Treatment of mesenteric desmoid tumours with the anti-oestrogenic agent toremifene: case histories and an overview of the literature." 02/01/1994 - "Management of desmoid tumours including a case report of toremifene." Get all the results and reference details, order at left...
5.	Body Weight (Weight, Body) 05/01/1994 - "Toremifene was also remarkably effective in inhibiting MNU-induced mammary tumorigenesis although this inhibition was achieved at a dose which caused a significant decrease in body weight gain" 11/01/1996 - "All doses of toremifene reduced food intake and body weight gain" 03/01/2001 - "A second experiment evaluated the efficacy of toremifene (7.0 mg/kg diet), an estrogen/anti-estrogen, and the effect of toremifene-matched body weight gain reduction that occurred during the study" 03/01/2001 - "Toremifene caused a chronic reduction in body weight that resulted in a 10% decrease in final body weight at the end of the study" 03/01/2001 - "Thus, the weight effects observed with toremifene, similar estrogens/anti-estrogens, and other classes of chemopreventive compounds (where chronic body weight reductions are 10% or less) imply that the body weight reduction has a limited effect on overall chemopreventive activity" Get all the results and reference details, order at left...
67 Diseases and 292 more articles analyzed in the Research Interface, order at left...

Related Drugs and Biologics

1.	Tamoxifen
2.	Toremifene (Fareston)
3.	Estrogen Receptor Modulators (Antiestrogen)
4.	Estrogens (Estrogen)
5.	triphenylethylene
6.	Hormones
7.	Gonadotropin-Releasing Hormone (GnRH)
8.	Cisplatin (Platino)
9.	Selective Estrogen Receptor Modulators (SERM)
10.	denosumab
157 Drugs and Important Bio-Agents and 246 more articles analyzed in the Research Interface, order at left...

Related Therapies and Procedures

1.	Drug Therapy (Chemotherapy)
2.	Immunotherapy
3.	Investigational Therapies (Experimental Therapy)
4.	Chemoprevention
5.	Heterologous Transplantation (Xenotransplantation)
9 Therapies and Procedures and 20 more articles analyzed in the Research Interface, order at left...

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License details >>

Price:

$490.00 access via web interface, 1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m", 1 year subscription

Proceed to Checkout >>